CytomX Therapeutics has provided an update on its CX-2051 Phase 1 study targeting colorectal cancer, reporting that 73 patients have been enrolled to date. The company remains on track to release additional Phase 1 data in the first quarter of 2026. The study involves the antibody-drug conjugate varsetatug masetecan (CX-2051), which is associated with expected side effects such as diarrhea due to its EpCAM × Topo-1 targeting mechanism. Despite prophylactic measures, gastrointestinal adverse events remain a challenge. Recently, a treatment-related patient death occurred due to kidney injury during the trial. Regulatory and advisory bodies have recommended continuation of the study despite this fatality. CytomX continues to advance the trial while monitoring safety outcomes closely.